Inclusion Criteria:

          -  Must provide written informed consent prior to initiating any trial related procedures

          -  Patient must be >= 18 years of age

          -  Patient has histologically confirmed (if tumor tissue is unavailable, documentation of
             diagnosis from original biopsy is acceptable) or clinically diagnosed (American
             Association for the Study of Liver Disease criteria in cirrhotic subjects)
             hepatocellular carcinoma (HCC)

          -  Patient has resectable disease with no evidence of extrahepatic spread

               -  The determination of resectability status will ultimately lie in the clinical
                  judgment of the surgical oncologist and medical oncologist involved in the care
                  of the patient based on the following tumor parameters: one single tumor =< 5 cm,
                  or largest tumor =< 5 cm and =< 3 tumors without vascular invasion on imaging

          -  Must have a Child-Turcotte-Pugh score A

          -  Must have measurable disease defined as a lesion that can be accurately measured in at
             least one dimension (longest diameter to be recorded) and that measures >= 10 mm with
             ultrasound (US), magnetic resonance imaging (MRI) or spiral computed tomography (CT)
             scan

          -  Patient has record of treated or absence of esophageal varices by
             esophagogastroduodenoscopy within 6 months of initiating treatment

          -  Patient must be have a representative tumor specimen or be willing to undergo research
             biopsy and provide tumor sample for exploratory biomarker research

          -  ECOG (Eastern Oncology Cooperative Group) performance status >= 1

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1500/uL) (within 14 days of study
             drug administration)

          -  Lymphocyte count >= 0.5 x 10^9/L (500/uL) (within 14 days of study drug
             administration)

          -  Platelet count >= 100 x 10^9/L (100,000/uL) without transfusion (within 14 days of
             study drug administration)

          -  Hemoglobin >= 90 g/L (9 g/dL) (within 14 days of study drug administration)

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline
             phosphatase (ALP) =< 2.5 x upper limit of normal (ULN) (within 14 days of study drug
             administration)

          -  Serum bilirubin =< 1.5 x ULN (within 14 days of study drug administration) with the
             following exception:

               -  Patients with known Gilbert disease: serum bilirubin =< 3 x ULN

          -  Serum creatinine =< 1.5 x ULN (within 14 days of study drug administration)

          -  Serum albumin >= 25 g/L (2.5 g/dL) (within 14 days of study drug administration)

          -  International normalized ratio (INR) or activated partial thromboplastin time (aPTT)
             =< 1.5 x ULN (within 14 days of study drug administration)

          -  Negative human immunodeficiency virus (HIV) test at screening (within 14 days of study
             drug administration)

          -  Urinalysis (UA) with protein less than 2+ (within 14 days of study drug
             administration)

          -  Documented virology status of hepatitis, as confirmed by screening hepatitis B virus
             (HBV) and hepatitis C virus (HCV) tests (within 14 days of study drug administration)

               -  For patients with active HBV: HBV deoxyribonucleic acid (DNA) < 500 IU/mL during
                  screening, initiation of anti-HBV treatment at least 14 days prior to
                  randomization and willingness to continue anti-HBV treatment during the study
                  (per local standard of care; e.g., entecavir)

          -  Women of childbearing potential (WOCBP) and men with partners of child bearing
             potential agree to prevent pregnancy using two forms of contraception from the date of
             informed consent through 5 months post last dose of study drug

          -  Women of child bearing potential must have a negative serum pregnancy test result
             within 14 days of initiating study treatment

          -  Women of child bearing potential must not be breastfeeding

        Exclusion Criteria:

          -  Patient has been treated for this malignancy, has another active malignancy, or has
             had an active malignancy within the last two years

          -  Patient has fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC

          -  Patient has had a bleeding event due to untreated esophageal and/or gastric varices

          -  Patient has history of abdominal or tracheoesophageal fistula, gastrointestinal (GI)
             perforation, or intra-abdominal abscess within 6 months of initiation of study
             treatment

          -  Patient has history of thrombosis, bleeding diathesis, coagulopathy or significant
             vascular disease

          -  Patient has history of hemoptysis within 30 days of initiation of study treatment

          -  Patient has serious cardiac disease, including New York Heart Association grade II or
             greater congestive heart failure, myocardial infarction (MI), unstable angina, etc

          -  Patient has inadequately controlled hypertension (systolic >= 150 mmHg and/or
             diastolic >= 100 mmHg)

          -  Patient has significant pulmonary disease including tuberculosis, pneumonia,
             pneumonitis, etc

          -  Patient requires recurrent drainage procedures including pleural effusion, ascites,
             etc

          -  Patient has had surgical procedure within 6 weeks of initiation of study treatment

          -  Patient has history of central nervous system disease

          -  Patient has history of severe allergic/anaphylactic reactions to chimeric or humanized
             antibodies or fusion proteins

          -  Patient has a known hypersensitivity to Chinese hamster ovary cell products or to any
             component of the atezolizumab formulation

          -  Patient has known hypersensitivity to bevacizumab

          -  Patient has had any investigational agents within 28 days prior to initiation of study
             treatment

          -  Patient has history of severe infection within 4 weeks of initiation of treatment

          -  Patient has history of auto immune disease or auto immune deficiency

          -  Patient has received stem cell transplantation, liver transplantation, or solid organ
             transplantation

          -  Patient has history of other significant comorbidities that would be contraindicated
             for investigational treatment

          -  Patient has used:

               -  High dose steroids

               -  Vaccine of any kind within 4 weeks of initiating study treatment

               -  Oral or IV antibiotics within 2 weeks of initiating study treatment

               -  Immunostimulatory agents within 4 weeks of initiating study treatment

               -  Anticoagulation therapy (aspirin permitted)

               -  Total parenteral nutrition

          -  Patient is pregnant or breastfeeding